Chris Gibson
April 21, 2019
Chris completed his PhD in Bioengineering at the University of Utah in the fall of 2013 before taking a leave of absence from medical school (he was enrolled in the MD/PhD program) to found and grow Recursion. He developed the core technology underlying this venture while in the lab of Dr. Dean Li. Chris comes from a family of entrepreneurs, is a graduate of Rice University with degrees in bioengineering and managerial studies, and recently completed an intense course in entrepreneurship at Stanford GSB. Chris is also a Board Member of CureHHT, a patient advocacy group for Hereditary Hemorrhagic Telangiectasia. Chris enjoys cycling on both the road and the trails that cut through Utah’s great wilderness, as well as spending precious time with his family.
Bio courtesy of recursion
Recent News
- bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
- DGENTHERA AND NUSANO SIGN LETTER OF INTENT FOR ASTATINE‑211 SUPPLY
- 2025 BIO International Recap
- Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation
- Nelson Labs to Double Cleanroom Capacity to Support Growing Demand for Sterility Assurance Services
- RATIO THERAPEUTICS AND NUSANO ENTER LONG-TERM, MULTI-ISOTOPE SUPPLY AGREEMENT TO BOOST PRODUCTION OF CANCER RADIOPHARMACEUTICALS